A La Jolla immunologist helped identify tiny food protein fragments that tell gut immune cells to tolerate corn, wheat and soy — a finding that could inform future allergy therapies.

Scripps researchers in La Jolla will lead NASA’s EDGE mission, using spaceborne lasers to produce dense 3‑D elevation maps that could sharpen flood and coastal planning.

A six‑planet parade arcs the western sky this Saturday, then a total lunar eclipse peaks around 3 a.m. PST next Tuesday. Times and local viewing tips for San Diego.

UC San Diego’s three‑hit model and international analyses link metabolic stress and parental chemical intolerance to autism risk, but experts urge caution. Larger trials are needed.

DOJ documents show Epstein’s money reached a UCSD lab after an introduction by Deepak Chopra; emails name a ‘telepathic’ autistic savant and a $25K payment.

San Diego’s Element Biosciences unveiled VITARI, a benchtop sequencer it says can deliver a whole genome for about $100. The launch comes as patent and antitrust fights with Illumina play out in federal court.

Seattle’s Highspot will merge with San Diego rival Seismic, combining two major revenue‑enablement platforms under a San Diego‑led brand and an AI‑first roadmap.

A Scripps diver filmed a rare prickly shark at La Jolla Cove during a night research dive. The footage highlights the shark’s thorny skin and posterior fins.

Two San Diego startups and Kratos SRE made the Pentagon’s Gauntlet shortlist. The trials begin next week and could lead to sizable prototype orders.

Federal and UK cyber agencies warn that unsupported routers, firewalls and VPNs are being targeted by nation‑state actors. Local IT teams should inventory, patch or replace at‑risk gear.

Halozyme raised 2026 guidance and acquired two hyperconcentration firms, projecting faster royalty growth and several clinic starts that could reshape local drug‑delivery work.

A San Diego‑led team mapped nine CD8 T‑cell states and identified two transcription factors that revive exhausted T cells without erasing immune memory. The finding points to new cell‑therapy strategies.

San Diego biotech Neomorph has dosed the first patient in a Phase 1/2 trial of NEO‑811, a molecular glue for clear‑cell kidney cancer, after landing multibillion‑dollar pharma deals. Early safety and activity readouts will be the near‑term test.